

JOIN US ON THE PATH TO POSSIBILITY

Lilly is dedicated to delivering life-changing medicines and support to people living with cancer. Please join us and our expert panel on the path to possibility as we pursue new medicines that bring new hope.

Industry Sponsored Symposium

PERSONALIZING AND OPTIMIZING TREATMENT FOR METASTATIC NSCLC PATIENTS WITH EGFR MUTATIONS—IS THERE MORE WE CAN DO?



IASLC 2021 World Conference on Lung Cancer | Worldwide Virtual Event
Lilly Virtual Symposium
Friday, Sep 10 / 5:45 – 6:45 a.m. MT

5 minutes	Welcome and introduction	Chair – Mark Socinski – US
15 minutes	Is a one-size-fits-all approach still appropriate for mNSCLC with an EGFR mutation? Are all mutations equal?	Silvia Novello – Italy
10 minutes	Could a dual-mechanism treatment approach impact patient outcomes?	Nobuyuki Takakura – Japan
10 minutes	Identifying the clinical and disease characteristics of the high-risk EGFRmut+ mNSCLC patient. What is the science telling us?	Myung-Ju Ahn – Korea
15 minutes	Panel discussion and Q&A	All panel
5 minutes	Closing remarks	Mark Socinski – US

Symposium Objectives

- Review the EGFRmut+ mNSCLC landscape and treatment outcomes of different mutations including common, rare, and co-occurring mutations
- Understand the scientific rationale behind combining therapies and the impact on treatment outcomes for EGFRmut+ mNSCLC patients
- Discuss high-risk clinical and disease characteristics of patients with EGFRmut+ mNSCLC including negative impact on prognosis and response to therapy and implications for optimizing treatment decision making and clinical outcomes